实用医学杂志 ›› 2023, Vol. 39 ›› Issue (9): 1164-1168.doi: 10.3969/j.issn.1006⁃5725.2023.09.018

• 药物与临床 • 上一篇    下一篇

艾塞那肽联合多烯磷脂酰胆碱对酒精性脂肪肝患者血清HMGB1、APN 水平的影响 

王蕾1 贵瑶瑶1 寇丽2    

  1. 1 首都医科大学附属北京佑安医院肝病中心三科(北京 100069);2 湖北文理学院附属医院襄阳市中心医院 普外三科(湖北襄阳 441021)
  • 出版日期:2023-05-10 发布日期:2023-05-10

Effect of exenatide combined with polyene phosphatidyl choline on serum HMGB1 and APN levels in pa⁃ tients with alcoholic fatty liver disease 

WANG Lei* ,GUI Yaoyao,KOU Li.    

  1. Department 3,Hepatology Center, Beijing You􀆳an Hospital,Capital Medical University,Beijing 100069,China 
  • Online:2023-05-10 Published:2023-05-10

摘要:

目的 分析艾塞那肽联合多烯磷脂酰胆碱治疗酒精性脂肪肝的效果及对血清高迁移率族 蛋白 B1(HMGB1)、脂联素(APN)水平的影响。方法 纳入我院 2020 年 1 月至 2022 年 1 月收治的酒精性脂 肪肝患者共 108 例,采用随机数字表法分为观察组和对照组,每组 54 例,对照组采用多烯磷脂酰胆碱治疗,观察组在对照组的基础上联合艾塞那肽治疗,观察两组患者的治疗效果和血清 HMGB1、APN 的水 平。结果 治疗 3 个月后,两组患者的临体征均明显改善,临床症状消失更快,观察组的临床总有效率 (96.30%)高于对照组(83.33%),差异有统计学意义(均 P < 0.05);治疗前两组患者血清 ALT、AST、TC、TG、 TBil 差异均无统计学意义(均 P > 0.05),治疗后两组患者的各项指标均显著下降,且观察组明显低于对照 组(P < 0.01);治疗前两组患者的血清 HMGB1、APN 水平差异无统计学意义,治疗后两组患者的血清 HMGB1 水平均显著下降(P < 0.001),且观察组患者的血清 HMGB1 水平明显低于对照组(P < 0.05);治疗后两组患者的血清 APN 水平均显著升高(P < 0.001),且观察组明显高于对照组(P < 0.05);两组不良反应 差异无统计学意义(P > 0.05)。结论 艾塞那肽联合多烯磷脂酰胆碱能够提高酒精性脂肪肝的治疗效 果,降低血清HMGB1水平并提高血清APN 水平,且安全性较好。 

关键词: 艾塞那肽, 多烯磷脂酰胆碱, 酒精性脂肪肝, HMGB1, APN

Abstract:

Objective To analyze the effect of exenatide combined with polyene phosphatidyl choline on alcoholic fatty liver disease and their effect on serum high mobility group protein B1(HMGB1)and adiponectin (APN)levels. Methods A total of 108 patients with alcoholic fatty liver disease admitted to our hospital from January 2020 to January 2022 were divided into observation group and control group by random number table meth⁃ od,with 54 cases in each group. The control group was treated with polyene phosphatidyl choline,and the observa⁃ tion group was treated with exenatide on the basis of control group. The therapeutic effect and serum levels of HMGB1 and APN in 2 groups were observed and compared between the two groups. Results After 3 months of treatment,the clinical symptoms of both groups were significantly improved and the clinical symptoms disappeared faster. The total clinical effective rate of the observation group was significantly higher than that of the control group (96.30% vs. 83.33%,P<0.05). There were no significant differences in the serum ALT,AST,TC,TG and TBil between the two groups before treatment(all P>0.05). After treatment,the all indexes of the two groups were sig⁃ nificantly decreased,and those of the observation group were lower than of the control group(P<0.01). There was no significant difference in the serum HMGB1 and APN levels between the two groups before treatment. After treat⁃ ment,the serum HMGB1 level in the two groups was significantly decreased(P<0.001),and the serum HMGB1 level in the observation group was lower than that in the control group(P<0.05). After treatment,the serum APN levels of both groups were significantly increased(P<0.001),and the level of observation group was significantly higher than of the control group(P<0.05). There was no significant difference in the adverse reactions between the two groups(P>0.05). Conclusion Exenatide combined with polyene phosphatidyl choline can improve the thera⁃ peutic effect of alcoholic fatty liver disease,reduce serum HMGB1 level and increase serum APN level safely. 

Key words: exenatide, polyene phosphatidyl choline, alcoholic fatty liver, HMGB1, APN